相关实验视频
Updated: Jan 17, 2026
05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
817
从跨越生物阿尔茨海默氏病阶段的纵向Tau-PET积累对临床试验的含义
Lydia Trudel1, Joseph Therriault1, Arthur C Macedo1
1Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Montreal Neurological Institute, Quebec, Canada.
Neurology
|September 23, 2025
概括
了解阿尔茨海默病 (AD) 阶段的积模式对于临床试验至关重要. 将tau-PET成像区域定制为AD阶段,通过减少所需样本大小,显著提高了试验效率.
科学领域:
- 神经成像是一种神经成像.
- 生物标志物 生物标志物
- 阿尔茨海默氏症疾病研究研究
背景情况:
- 在阿尔茨海默病 (AD) 临床试验中,tau-PET成像非常重要,有助于参与者选择和结果测量.
- 跨不同AD阶段的纵向积模式需要进一步澄清,以优化试验设计.
研究的目的:
- 在不同的AD阶段调查纵向的tau-PET积累模式.
- 通过澄清特定阶段的tau进展来为阿尔茨海默病临床试验设计提供信息.
主要方法:
- 对来自两个纵向队列 (TRIAD和ADNI) 的542名参与者的回顾性分析.
- 参与者通过使用粉样蛋白-PET和-PET吸收 (A+T2-,A+T2MTL+,A+T2MOD+,A+T2HIGH+) 来进行生物分期.
- 线性混合效应模型和功率分析评估了特定阶段的tau-PET变化和样本大小要求.
主要成果:
- 基线AD阶段决定了tau积累的区域分布和规模.
- 在初始阶段 (A+T2-) 没有观察到显著的积.
- 陶积累进展到特定的区域,与整个队列的早期,中期和高级AD阶段一致.
结论:
- 特定阶段的tau-PET模式强调了基线生物分期对于选择结果区域的重要性.
- 将结果区域与疾病阶段对齐可以大幅减少估计的样本大小,提高试验效率.
- 调查结果在所有队伍中都是一致的,尽管标志物和人口统计学差异是已知的局限性.
相关概念视频
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:26Longitudinal Studies
481
Longitudinal studies are also widely used in other medical and social science fields. For instance, in cardiovascular research, they can monitor patients' health over decades to identify risk factors for heart disease, such as high cholesterol or smoking, and evaluate the long-term effectiveness of preventive measures. Similarly, in mental health studies, researchers might follow individuals from adolescence into adulthood to understand the development and progression of conditions like...
481
02:20Longitudinal Research
13.1K
Sometimes we want to see how people change over time, as in studies of human development and lifespan. When we test the same group of individuals repeatedly over an extended period of time, we are conducting longitudinal research. Longitudinal research is a research design in which data-gathering is administered repeatedly over an extended period of time. For example, we may survey a group of individuals about their dietary habits at age 20, retest them a decade later at age 30, and then again...
13.1K
01:22Alzheimer's Disease: Treatment
825
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
825